Zobrazeno 1 - 10
of 204
pro vyhledávání: '"Matteo, Landriscina"'
Autor:
Piera Soccio, Giorgia Moriondo, Giulia Scioscia, Pasquale Tondo, Giuseppina Bruno, Guido Giordano, Roberto Sabato, Maria Pia Foschino Barbaro, Matteo Landriscina, Donato Lacedonia
Publikováno v:
Non-coding RNA Research, Vol 10, Iss , Pp 91-97 (2025)
Introduction: The relationship between obstructive sleep apnea (OSA) and cancer has been recognized for some time now. However, little is known about the mechanisms by which sleep apnea promotes tumorigenesis and the impact of OSA on survival after c
Externí odkaz:
https://doaj.org/article/89770f2376e24b00b47f010442751697
Autor:
Guido Giordano, Michele Milella, Matteo Landriscina, Francesca Bergamo, Giuseppe Tirino, Antonio Santaniello, Alberto Zaniboni, Enrico Vasile, Ferdinando De Vita, Giovanni Lo Re, Vanja Vaccaro, Elisa Giommoni, Donato Natale, Raffaele Conca, Daniele Santini, Luigi Maiorino, Gianni Sanna, Vincenzo Ricci, Aldo Iop, Vincenzo Montesarchio, Letizia Procaccio, Silvia Noventa, Roberto Bianco, Antonio Febbraro, Sara Lonardi, Giampaolo Tortora, Isabella Sperduti, Davide Melisi
Publikováno v:
Cancer Medicine, Vol 13, Iss 12, Pp n/a-n/a (2024)
Abstract Background Pancreatic cancer (PC) first‐line therapy often consists of polychemotherapy regimens, but choosing a second‐line therapy after disease progression, especially following first‐line FOLFIRINOX, remains a clinical challenge. T
Externí odkaz:
https://doaj.org/article/cf916ab2ef1c4b38b23365ff3e0dccbd
Autor:
Marianna Garofoli, Brigida Anna Maiorano, Giuseppina Bruno, Guido Giordano, Piergiorgio Di Tullio, Felicia Maria Maselli, Matteo Landriscina, Vincenza Conteduca
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 16 (2024)
Aberrations in the homologous recombination repair (HRR) pathway in prostate cancer (PCa) provide a unique opportunity to develop therapeutic strategies that take advantage of the reduced tumor ability to repair DNA damage. Poly-ADP-ribose polymerase
Externí odkaz:
https://doaj.org/article/a95b870f22bb498c96eca339ffb5dcc7
Autor:
Danilo Swann Matassa, Daniela Criscuolo, Rosario Avolio, Ilenia Agliarulo, Daniela Sarnataro, Consiglia Pacelli, Rosella Scrima, Alessandra Colamatteo, Giuseppe Matarese, Nazzareno Capitanio, Matteo Landriscina, Franca Esposito
Publikováno v:
Cancer Cell International, Vol 22, Iss 1, Pp 1-18 (2022)
Abstract Background Metabolic reprogramming is an important issue in tumor biology. A recently-identified actor in this regard is the molecular chaperone TRAP1, that is considered an oncogene in several cancers for its high expression but an oncosupp
Externí odkaz:
https://doaj.org/article/a508672b12454c2387d8c9dd1905a580
Autor:
Francesca Pia Caruso, Mario Rosario D’Andrea, Luigi Coppola, Matteo Landriscina, Valentina Condelli, Luigi Cerulo, Guido Giordano, Almudena Porras, Massimo Pancione
Publikováno v:
Cancer Cell International, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract In addition to being novel biomarkers for poor cancer prognosis, members of Lymphocyte antigen-6 (Ly6) gene family also play a crucial role in avoiding immune responses to tumors. However, it has not been possible to identify the underlying
Externí odkaz:
https://doaj.org/article/86c34b9740db494db12496f33c51bbe9
Autor:
Alessandro Parisi, Riccardo Giampieri, Alex Mammarella, Cristiano Felicetti, Lisa Salvatore, Maria Bensi, Maria Grazia Maratta, Antonia Strippoli, Roberto Filippi, Maria Antonietta Satolli, Angelica Petrillo, Bruno Daniele, Michele De Tursi, Pietro Di Marino, Guido Giordano, Matteo Landriscina, Pasquale Vitale, Ina Valeria Zurlo, Emanuela Dell’Aquila, Silverio Tomao, Ilaria Depetris, Francesca Romana Di Pietro, Federica Zoratto, Davide Ciardiello, Maria Vittoria Pensieri, Ornella Garrone, Barbara Galassi, Claudio Ferri, Rossana Berardi, Michele Ghidini
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
AimThe aim of the current study is to investigate the impact of primary compared to secondary chemotherapy-induced nausea and vomiting (CINV) prophylaxis with NK1 receptor antagonists (NK1-RA) in patients affected by gastrointestinal malignancies and
Externí odkaz:
https://doaj.org/article/a870c172dbe94deaa83affaa21374c17
Autor:
Nadia Melillo, Matteo Landriscina, Antonello Trotta, Stefania Sciacca, Francesco Paolo Cantatore
Publikováno v:
Beyond Rheumatology, Vol 3 (2021)
The association between estrogen receptor (ER) positive breast cancer (BC) and autoimmune disorders has been recently recognized. In particular exposure to aromatase inhibitors is associated with a significant increased risk of rheumatological autoim
Externí odkaz:
https://doaj.org/article/2edbd467649947f1aff95dc1d54d2734
Autor:
Augusto Leone, Antonio Colamaria, Nicola Pio Fochi, Matteo Sacco, Matteo Landriscina, Giovanni Parbonetti, Matteo de Notaris, Giulia Coppola, Elena De Santis, Guido Giordano, Francesco Carbone
Publikováno v:
Biomedicines, Vol 10, Iss 8, p 1927 (2022)
Current treatment guidelines for the management of recurrent glioblastoma (rGBM) are far from definitive, and the prognosis remains dismal. Despite recent advancements in the pharmacological and surgical fields, numerous doubts persist concerning the
Externí odkaz:
https://doaj.org/article/2aee60f589a14e8e8107728ce17fde13
Autor:
Francesca Sanguedolce, Magda Zanelli, Andrea Palicelli, Stefano Ascani, Maurizio Zizzo, Giorgia Cocco, Lars Björnebo, Anna Lantz, Matteo Landriscina, Vincenza Conteduca, Ugo Giovanni Falagario, Luigi Cormio, Giuseppe Carrieri
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 14, p 7844 (2022)
Following several attempts to achieve a molecular stratification of bladder cancer (BC) over the last decade, a “consensus” classification has been recently developed to provide a common base for the molecular classification of bladder cancer (BC
Externí odkaz:
https://doaj.org/article/e6433e171b234a69b0190b45fdec3b0b
Autor:
Andrea Palicelli, Stefania Croci, Alessandra Bisagni, Eleonora Zanetti, Dario De Biase, Beatrice Melli, Francesca Sanguedolce, Moira Ragazzi, Magda Zanelli, Alcides Chaux, Sofia Cañete-Portillo, Maria Paola Bonasoni, Stefano Ascani, Antonio De Leo, Guido Giordano, Matteo Landriscina, Giuseppe Carrieri, Luigi Cormio, Jatin Gandhi, Davide Nicoli, Enrico Farnetti, Simonetta Piana, Alessandro Tafuni, Martina Bonacini
Publikováno v:
Biomedicines, Vol 10, Iss 2, p 236 (2022)
Pembrolizumab (anti-PD-1) is allowed in selected metastatic castration-resistant prostate cancer (PC) patients showing microsatellite instability/mismatch repair system deficiency (MSI-H/dMMR). BRCA1/2 loss-of-function is linked to hereditary PCs and
Externí odkaz:
https://doaj.org/article/bbb5dfa57c564073ba1cde3a06351b4f